| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antineoplastic Combined Chemotherapy Protocols | 46 | 2026 | 2658 | 2.780 |
Why?
|
| Randomized Controlled Trials as Topic | 14 | 2025 | 1012 | 2.520 |
Why?
|
| Survival Analysis | 17 | 2025 | 1527 | 1.750 |
Why?
|
| Clinical Trials, Phase II as Topic | 10 | 2024 | 168 | 1.690 |
Why?
|
| Research Design | 11 | 2024 | 660 | 1.670 |
Why?
|
| Antineoplastic Agents | 28 | 2020 | 2373 | 1.220 |
Why?
|
| Neoplasms | 25 | 2025 | 3334 | 1.140 |
Why?
|
| Humans | 276 | 2026 | 98135 | 1.120 |
Why?
|
| Neoplasm Recurrence, Local | 17 | 2026 | 1535 | 1.100 |
Why?
|
| Prostatic Neoplasms | 20 | 2025 | 1836 | 1.090 |
Why?
|
| Head and Neck Neoplasms | 16 | 2022 | 1088 | 1.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 5 | 2022 | 169 | 1.000 |
Why?
|
| Data Interpretation, Statistical | 5 | 2025 | 313 | 0.980 |
Why?
|
| Aged | 114 | 2026 | 21760 | 0.970 |
Why?
|
| Male | 171 | 2026 | 47109 | 0.950 |
Why?
|
| Lung Neoplasms | 16 | 2024 | 2457 | 0.950 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2025 | 195 | 0.920 |
Why?
|
| Aged, 80 and over | 68 | 2025 | 7387 | 0.920 |
Why?
|
| Middle Aged | 123 | 2026 | 29442 | 0.910 |
Why?
|
| Female | 178 | 2026 | 51570 | 0.900 |
Why?
|
| Clinical Trials as Topic | 9 | 2024 | 1131 | 0.870 |
Why?
|
| Biometry | 1 | 2025 | 70 | 0.860 |
Why?
|
| Multiple Myeloma | 6 | 2026 | 369 | 0.850 |
Why?
|
| Adult | 123 | 2026 | 29564 | 0.840 |
Why?
|
| Kidney Neoplasms | 11 | 2022 | 556 | 0.820 |
Why?
|
| Treatment Outcome | 55 | 2025 | 9713 | 0.800 |
Why?
|
| Phenylurea Compounds | 9 | 2014 | 112 | 0.790 |
Why?
|
| Radiosurgery | 6 | 2024 | 351 | 0.790 |
Why?
|
| Antibodies, Monoclonal, Humanized | 15 | 2023 | 1099 | 0.700 |
Why?
|
| Carcinoma, Squamous Cell | 11 | 2022 | 1105 | 0.680 |
Why?
|
| Carcinoma, Renal Cell | 8 | 2022 | 384 | 0.670 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 8 | 2021 | 1173 | 0.660 |
Why?
|
| Maximum Tolerated Dose | 10 | 2025 | 265 | 0.660 |
Why?
|
| Protein Kinase Inhibitors | 10 | 2022 | 640 | 0.650 |
Why?
|
| Proportional Hazards Models | 9 | 2025 | 922 | 0.650 |
Why?
|
| Air Pollution, Indoor | 5 | 2021 | 82 | 0.650 |
Why?
|
| Leukemia, Myeloid, Acute | 9 | 2025 | 849 | 0.640 |
Why?
|
| Androgen Antagonists | 8 | 2025 | 157 | 0.640 |
Why?
|
| Glucuronosyltransferase | 6 | 2020 | 178 | 0.600 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 7 | 2026 | 977 | 0.590 |
Why?
|
| Benzimidazoles | 2 | 2017 | 118 | 0.570 |
Why?
|
| Ambulances | 1 | 2018 | 16 | 0.560 |
Why?
|
| Adenocarcinoma | 12 | 2023 | 1211 | 0.560 |
Why?
|
| Dose-Response Relationship, Drug | 15 | 2020 | 1950 | 0.550 |
Why?
|
| Quinazolines | 8 | 2023 | 221 | 0.550 |
Why?
|
| Dexamethasone | 8 | 2026 | 318 | 0.540 |
Why?
|
| Cooking | 4 | 2021 | 71 | 0.530 |
Why?
|
| Antineoplastic Agents, Immunological | 6 | 2025 | 237 | 0.530 |
Why?
|
| Disease-Free Survival | 18 | 2026 | 1193 | 0.520 |
Why?
|
| Statistics, Nonparametric | 7 | 2025 | 303 | 0.510 |
Why?
|
| Time Factors | 30 | 2025 | 5576 | 0.510 |
Why?
|
| Quinolines | 2 | 2020 | 97 | 0.510 |
Why?
|
| Prospective Studies | 36 | 2025 | 4825 | 0.510 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 4 | 2022 | 117 | 0.510 |
Why?
|
| Breast Neoplasms | 16 | 2026 | 3272 | 0.500 |
Why?
|
| Oligopeptides | 4 | 2026 | 207 | 0.480 |
Why?
|
| Stomach Neoplasms | 6 | 2020 | 319 | 0.470 |
Why?
|
| Endpoint Determination | 2 | 2024 | 66 | 0.470 |
Why?
|
| Wounds and Injuries | 2 | 2018 | 305 | 0.460 |
Why?
|
| Pyridines | 7 | 2015 | 318 | 0.460 |
Why?
|
| Neoplasm Metastasis | 13 | 2020 | 1089 | 0.450 |
Why?
|
| Pharmacogenetics | 6 | 2025 | 472 | 0.450 |
Why?
|
| Hospital Mortality | 1 | 2018 | 541 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 7 | 2024 | 1416 | 0.450 |
Why?
|
| Sirolimus | 5 | 2022 | 182 | 0.450 |
Why?
|
| Indoles | 6 | 2023 | 334 | 0.440 |
Why?
|
| Niacinamide | 8 | 2014 | 105 | 0.440 |
Why?
|
| Toxoplasmosis, Congenital | 6 | 2015 | 47 | 0.440 |
Why?
|
| Chicago | 17 | 2020 | 1513 | 0.420 |
Why?
|
| Camptothecin | 6 | 2014 | 198 | 0.420 |
Why?
|
| Neoplasm Staging | 18 | 2025 | 2080 | 0.410 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2015 | 153 | 0.410 |
Why?
|
| Esophageal Neoplasms | 6 | 2020 | 353 | 0.410 |
Why?
|
| Medical Oncology | 3 | 2024 | 421 | 0.410 |
Why?
|
| Hodgkin Disease | 6 | 2023 | 145 | 0.410 |
Why?
|
| Allergens | 4 | 1998 | 196 | 0.400 |
Why?
|
| Metformin | 3 | 2025 | 132 | 0.400 |
Why?
|
| Ovarian Neoplasms | 5 | 2025 | 825 | 0.400 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 532 | 0.400 |
Why?
|
| Paclitaxel | 8 | 2025 | 483 | 0.400 |
Why?
|
| Oropharyngeal Neoplasms | 4 | 2022 | 152 | 0.390 |
Why?
|
| Computer Simulation | 3 | 2025 | 1153 | 0.390 |
Why?
|
| Combined Modality Therapy | 14 | 2025 | 1751 | 0.380 |
Why?
|
| Sulfonamides | 5 | 2016 | 351 | 0.370 |
Why?
|
| Pneumonectomy | 2 | 2008 | 222 | 0.370 |
Why?
|
| Blood Pressure | 5 | 2024 | 910 | 0.360 |
Why?
|
| Colorectal Neoplasms | 2 | 2026 | 1103 | 0.360 |
Why?
|
| Papillomavirus Infections | 4 | 2022 | 310 | 0.360 |
Why?
|
| Cetuximab | 4 | 2020 | 119 | 0.360 |
Why?
|
| Survival Rate | 15 | 2024 | 2041 | 0.360 |
Why?
|
| Aneurysm, Ruptured | 2 | 2003 | 80 | 0.360 |
Why?
|
| Angiogenesis Inhibitors | 5 | 2016 | 280 | 0.360 |
Why?
|
| Pharmacogenomic Testing | 3 | 2025 | 119 | 0.360 |
Why?
|
| Neoplasm, Residual | 5 | 2024 | 206 | 0.350 |
Why?
|
| Prognosis | 24 | 2026 | 4116 | 0.350 |
Why?
|
| Models, Statistical | 5 | 2025 | 601 | 0.350 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2025 | 159 | 0.350 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 5 | 2015 | 82 | 0.350 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 212 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 3 | 2026 | 478 | 0.340 |
Why?
|
| Azacitidine | 3 | 2024 | 152 | 0.340 |
Why?
|
| Sample Size | 3 | 2007 | 130 | 0.340 |
Why?
|
| Biomarkers, Tumor | 12 | 2024 | 1764 | 0.340 |
Why?
|
| Androgens | 5 | 2023 | 164 | 0.340 |
Why?
|
| Chemoradiotherapy | 5 | 2022 | 337 | 0.330 |
Why?
|
| Adolescent | 28 | 2026 | 10097 | 0.330 |
Why?
|
| Disease Progression | 11 | 2023 | 1610 | 0.330 |
Why?
|
| Vascular Endothelial Growth Factor A | 7 | 2023 | 400 | 0.320 |
Why?
|
| Pleural Neoplasms | 3 | 2018 | 207 | 0.320 |
Why?
|
| Radiation Oncology | 2 | 2022 | 130 | 0.320 |
Why?
|
| Papillomaviridae | 3 | 2022 | 184 | 0.320 |
Why?
|
| Carcinoma | 7 | 2015 | 440 | 0.320 |
Why?
|
| Myelodysplastic Syndromes | 4 | 2016 | 385 | 0.320 |
Why?
|
| Trastuzumab | 3 | 2026 | 98 | 0.310 |
Why?
|
| Pregnancy | 18 | 2021 | 3244 | 0.310 |
Why?
|
| Neoplasms, Experimental | 3 | 2019 | 261 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 401 | 0.300 |
Why?
|
| Benzenesulfonates | 4 | 2012 | 49 | 0.300 |
Why?
|
| Mesothelioma | 3 | 2018 | 346 | 0.290 |
Why?
|
| Injury Severity Score | 2 | 2021 | 165 | 0.290 |
Why?
|
| Antineoplastic Agents, Phytogenic | 5 | 2014 | 272 | 0.290 |
Why?
|
| Fluorouracil | 9 | 2020 | 541 | 0.290 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2024 | 39 | 0.290 |
Why?
|
| Receptors, Glucocorticoid | 3 | 2025 | 145 | 0.280 |
Why?
|
| Genotype | 13 | 2022 | 1888 | 0.280 |
Why?
|
| Robotic Surgical Procedures | 3 | 2025 | 411 | 0.280 |
Why?
|
| Young Adult | 15 | 2026 | 7511 | 0.280 |
Why?
|
| Drug Resistance, Neoplasm | 5 | 2020 | 665 | 0.280 |
Why?
|
| Laparoscopy | 3 | 2025 | 792 | 0.280 |
Why?
|
| Anesthesiology | 2 | 2022 | 171 | 0.280 |
Why?
|
| Ethanol | 4 | 2021 | 282 | 0.280 |
Why?
|
| Pyrimidines | 4 | 2016 | 413 | 0.270 |
Why?
|
| Toxoplasma | 3 | 2015 | 114 | 0.270 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2019 | 112 | 0.270 |
Why?
|
| Serum Albumin | 1 | 2008 | 126 | 0.270 |
Why?
|
| Prostate-Specific Antigen | 11 | 2023 | 354 | 0.270 |
Why?
|
| Retrospective Studies | 23 | 2023 | 10962 | 0.260 |
Why?
|
| Double-Blind Method | 16 | 2025 | 1783 | 0.260 |
Why?
|
| Abortion, Habitual | 4 | 2001 | 31 | 0.260 |
Why?
|
| Small Cell Lung Carcinoma | 2 | 2024 | 140 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-met | 4 | 2014 | 199 | 0.250 |
Why?
|
| Data Collection | 5 | 2009 | 376 | 0.250 |
Why?
|
| Likelihood Functions | 2 | 2025 | 258 | 0.240 |
Why?
|
| Polymorphism, Genetic | 4 | 2019 | 831 | 0.240 |
Why?
|
| Chromosome Aberrations | 4 | 2007 | 352 | 0.230 |
Why?
|
| Quality of Life | 9 | 2024 | 1895 | 0.230 |
Why?
|
| Biomarkers | 7 | 2022 | 2022 | 0.230 |
Why?
|
| Nigeria | 6 | 2026 | 174 | 0.230 |
Why?
|
| ErbB Receptors | 5 | 2020 | 516 | 0.230 |
Why?
|
| Bayes Theorem | 1 | 2007 | 422 | 0.230 |
Why?
|
| Asthma | 3 | 1998 | 1078 | 0.220 |
Why?
|
| Molecular Targeted Therapy | 3 | 2020 | 321 | 0.220 |
Why?
|
| Hemostatics | 1 | 2025 | 64 | 0.220 |
Why?
|
| Postoperative Hemorrhage | 1 | 2025 | 55 | 0.220 |
Why?
|
| Tumor Escape | 2 | 2017 | 55 | 0.220 |
Why?
|
| Leukemia | 3 | 2006 | 308 | 0.220 |
Why?
|
| Interleukin-2 | 3 | 2012 | 246 | 0.220 |
Why?
|
| Mastectomy, Radical | 2 | 1999 | 10 | 0.220 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2023 | 327 | 0.220 |
Why?
|
| Oncogene Proteins, Viral | 2 | 2020 | 33 | 0.220 |
Why?
|
| Blood Loss, Surgical | 1 | 2025 | 139 | 0.220 |
Why?
|
| Leucovorin | 4 | 2020 | 205 | 0.220 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 168 | 0.220 |
Why?
|
| Patient Portals | 1 | 2025 | 36 | 0.210 |
Why?
|
| Drug Monitoring | 3 | 2022 | 166 | 0.210 |
Why?
|
| Uterine Myomectomy | 1 | 2024 | 10 | 0.210 |
Why?
|
| Benzodioxoles | 2 | 2015 | 15 | 0.210 |
Why?
|
| Blood Pressure Determination | 1 | 2024 | 72 | 0.210 |
Why?
|
| Anilides | 2 | 2015 | 50 | 0.210 |
Why?
|
| Ipilimumab | 2 | 2021 | 68 | 0.210 |
Why?
|
| Neoplasm Grading | 3 | 2024 | 422 | 0.210 |
Why?
|
| Primary Myelofibrosis | 1 | 2024 | 72 | 0.210 |
Why?
|
| Cytokines | 4 | 2023 | 889 | 0.210 |
Why?
|
| Pregnancy Outcome | 7 | 2017 | 277 | 0.200 |
Why?
|
| Wearable Electronic Devices | 1 | 2024 | 45 | 0.200 |
Why?
|
| Perioperative Care | 3 | 2022 | 198 | 0.200 |
Why?
|
| Thrombosis | 2 | 2022 | 318 | 0.200 |
Why?
|
| Pregnatrienes | 1 | 2003 | 14 | 0.200 |
Why?
|
| Standard of Care | 1 | 2024 | 70 | 0.200 |
Why?
|
| Early Growth Response Protein 1 | 2 | 2013 | 58 | 0.200 |
Why?
|
| Lymphoma, Non-Hodgkin | 6 | 2013 | 262 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 6 | 2018 | 903 | 0.200 |
Why?
|
| Nephrectomy | 1 | 2025 | 290 | 0.200 |
Why?
|
| Cystectomy | 1 | 2024 | 124 | 0.200 |
Why?
|
| Vasospasm, Intracranial | 1 | 2003 | 38 | 0.200 |
Why?
|
| Haploinsufficiency | 2 | 2013 | 72 | 0.190 |
Why?
|
| C-Reactive Protein | 2 | 2022 | 208 | 0.190 |
Why?
|
| Prostate | 3 | 2022 | 434 | 0.190 |
Why?
|
| Postoperative Complications | 5 | 2019 | 2680 | 0.190 |
Why?
|
| Mastectomy | 4 | 2015 | 271 | 0.190 |
Why?
|
| Rituximab | 2 | 2025 | 135 | 0.190 |
Why?
|
| Carboplatin | 5 | 2025 | 331 | 0.190 |
Why?
|
| Inflammation | 2 | 2022 | 1120 | 0.190 |
Why?
|
| Chromosome Deletion | 2 | 2013 | 214 | 0.190 |
Why?
|
| Aneurysm | 1 | 2003 | 59 | 0.190 |
Why?
|
| CD8-Positive T-Lymphocytes | 3 | 2019 | 696 | 0.190 |
Why?
|
| Follow-Up Studies | 15 | 2023 | 4026 | 0.190 |
Why?
|
| Melanoma | 2 | 2021 | 524 | 0.190 |
Why?
|
| Neuroprotective Agents | 1 | 2003 | 94 | 0.190 |
Why?
|
| Tumor Burden | 5 | 2017 | 333 | 0.190 |
Why?
|
| Dioxolanes | 1 | 2002 | 8 | 0.190 |
Why?
|
| Probability | 2 | 2022 | 356 | 0.180 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2003 | 159 | 0.180 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2013 | 100 | 0.180 |
Why?
|
| Intracranial Arteriosclerosis | 1 | 2023 | 74 | 0.180 |
Why?
|
| Bacteria | 2 | 2026 | 545 | 0.180 |
Why?
|
| Particulate Matter | 2 | 2021 | 138 | 0.180 |
Why?
|
| Air Pollutants | 2 | 2021 | 116 | 0.180 |
Why?
|
| Deoxycytidine | 6 | 2025 | 217 | 0.180 |
Why?
|
| Tramadol | 1 | 2022 | 14 | 0.180 |
Why?
|
| Papillomavirus E7 Proteins | 2 | 2020 | 30 | 0.180 |
Why?
|
| Database Management Systems | 1 | 2002 | 44 | 0.180 |
Why?
|
| Cytosine | 1 | 2002 | 124 | 0.170 |
Why?
|
| Prostatectomy | 2 | 2016 | 490 | 0.170 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2001 | 8 | 0.170 |
Why?
|
| Cockroaches | 2 | 1998 | 10 | 0.170 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 358 | 0.170 |
Why?
|
| Glioblastoma | 1 | 2024 | 299 | 0.170 |
Why?
|
| Repressor Proteins | 2 | 2020 | 447 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2016 | 403 | 0.170 |
Why?
|
| Fetal Development | 1 | 2021 | 37 | 0.170 |
Why?
|
| Androstenes | 2 | 2018 | 41 | 0.170 |
Why?
|
| Cisplatin | 5 | 2023 | 578 | 0.170 |
Why?
|
| Amitriptyline | 1 | 2001 | 11 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2019 | 212 | 0.170 |
Why?
|
| Neoplasm Proteins | 3 | 2016 | 551 | 0.170 |
Why?
|
| Administration, Oral | 11 | 2020 | 674 | 0.170 |
Why?
|
| Hypertension | 3 | 2017 | 778 | 0.170 |
Why?
|
| Immunity | 1 | 2022 | 160 | 0.170 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2022 | 220 | 0.160 |
Why?
|
| Household Articles | 2 | 2017 | 17 | 0.160 |
Why?
|
| DNA, Viral | 1 | 2022 | 238 | 0.160 |
Why?
|
| Capecitabine | 2 | 2019 | 103 | 0.160 |
Why?
|
| Immunoassay | 2 | 2019 | 102 | 0.160 |
Why?
|
| Academic Medical Centers | 3 | 2019 | 413 | 0.160 |
Why?
|
| Transplantation, Autologous | 5 | 2026 | 395 | 0.160 |
Why?
|
| Neoplasm Transplantation | 2 | 2019 | 399 | 0.160 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 379 | 0.160 |
Why?
|
| Alleles | 6 | 2013 | 1159 | 0.160 |
Why?
|
| Naltrexone | 4 | 2005 | 140 | 0.160 |
Why?
|
| Epothilones | 2 | 2013 | 13 | 0.160 |
Why?
|
| Cerebral Angiography | 1 | 2002 | 263 | 0.160 |
Why?
|
| Vaginal Neoplasms | 1 | 2020 | 84 | 0.160 |
Why?
|
| Uterine Neoplasms | 2 | 2024 | 289 | 0.160 |
Why?
|
| Carcinogens | 1 | 2020 | 101 | 0.160 |
Why?
|
| Pyrrolidinones | 1 | 2020 | 15 | 0.160 |
Why?
|
| Leiomyoma | 1 | 2024 | 225 | 0.160 |
Why?
|
| Cell Cycle Proteins | 3 | 2016 | 419 | 0.160 |
Why?
|
| Narcotic Antagonists | 4 | 2005 | 181 | 0.160 |
Why?
|
| Antidepressive Agents | 1 | 2001 | 118 | 0.160 |
Why?
|
| Gait | 1 | 2001 | 88 | 0.160 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2022 | 116 | 0.160 |
Why?
|
| Mice | 17 | 2023 | 12697 | 0.160 |
Why?
|
| Anesthesia | 1 | 2022 | 174 | 0.160 |
Why?
|
| Blood Coagulation Disorders | 1 | 2021 | 67 | 0.160 |
Why?
|
| Chromosome Fragile Sites | 2 | 2010 | 5 | 0.150 |
Why?
|
| Mitoxantrone | 1 | 2020 | 65 | 0.150 |
Why?
|
| Fever | 1 | 2020 | 122 | 0.150 |
Why?
|
| Mifepristone | 3 | 2025 | 56 | 0.150 |
Why?
|
| Estrogens | 1 | 2020 | 201 | 0.150 |
Why?
|
| Head Injuries, Penetrating | 1 | 2021 | 70 | 0.150 |
Why?
|
| Drug Administration Schedule | 7 | 2020 | 839 | 0.150 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 2 | 2023 | 58 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2019 | 22 | 0.150 |
Why?
|
| Celecoxib | 1 | 2019 | 34 | 0.150 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 116 | 0.150 |
Why?
|
| Neurosurgical Procedures | 1 | 2003 | 402 | 0.150 |
Why?
|
| Intracranial Aneurysm | 1 | 2002 | 239 | 0.150 |
Why?
|
| Infant, Newborn | 15 | 2017 | 2531 | 0.150 |
Why?
|
| B7-H1 Antigen | 2 | 2023 | 332 | 0.150 |
Why?
|
| Clinical Chemistry Tests | 1 | 2019 | 11 | 0.150 |
Why?
|
| Ileal Diseases | 1 | 2019 | 24 | 0.140 |
Why?
|
| Pyrroles | 3 | 2015 | 165 | 0.140 |
Why?
|
| Ulcer | 1 | 2019 | 38 | 0.140 |
Why?
|
| Brain Ischemia | 1 | 2023 | 416 | 0.140 |
Why?
|
| Confidence Intervals | 2 | 1996 | 220 | 0.140 |
Why?
|
| Cohort Studies | 10 | 2021 | 3213 | 0.140 |
Why?
|
| Geographic Mapping | 1 | 2018 | 15 | 0.140 |
Why?
|
| Electroconvulsive Therapy | 1 | 2019 | 26 | 0.140 |
Why?
|
| Etoposide | 3 | 2025 | 207 | 0.140 |
Why?
|
| Kerosene | 4 | 2021 | 18 | 0.140 |
Why?
|
| Child, Preschool | 13 | 2016 | 4006 | 0.140 |
Why?
|
| TOR Serine-Threonine Kinases | 5 | 2022 | 220 | 0.140 |
Why?
|
| Mutation | 8 | 2023 | 4392 | 0.140 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2026 | 661 | 0.140 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2015 | 80 | 0.140 |
Why?
|
| Remission Induction | 5 | 2025 | 754 | 0.140 |
Why?
|
| Neuroblastoma | 1 | 2022 | 409 | 0.140 |
Why?
|
| Hyperparathyroidism, Primary | 1 | 2019 | 51 | 0.140 |
Why?
|
| Adoptive Transfer | 2 | 2017 | 174 | 0.140 |
Why?
|
| Thyroid Neoplasms | 1 | 2023 | 469 | 0.140 |
Why?
|
| Analysis of Variance | 4 | 2010 | 889 | 0.140 |
Why?
|
| Parathyroidectomy | 1 | 2019 | 87 | 0.140 |
Why?
|
| Ileum | 1 | 2019 | 172 | 0.140 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2021 | 134 | 0.140 |
Why?
|
| Induction Chemotherapy | 4 | 2022 | 151 | 0.140 |
Why?
|
| Animals | 30 | 2023 | 28902 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2019 | 132 | 0.140 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2022 | 443 | 0.130 |
Why?
|
| Recurrence | 6 | 2023 | 1254 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2012 | 1286 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2024 | 842 | 0.130 |
Why?
|
| Parathyroid Hormone | 1 | 2019 | 233 | 0.130 |
Why?
|
| Pancreatic Neoplasms | 3 | 2019 | 769 | 0.130 |
Why?
|
| Salvage Therapy | 3 | 2022 | 239 | 0.130 |
Why?
|
| Antigens, Neoplasm | 3 | 2017 | 361 | 0.130 |
Why?
|
| Food | 1 | 2018 | 93 | 0.130 |
Why?
|
| Necrosis | 1 | 2018 | 212 | 0.130 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2020 | 323 | 0.130 |
Why?
|
| Trauma Centers | 1 | 2018 | 199 | 0.130 |
Why?
|
| Pain Management | 1 | 2019 | 194 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2019 | 446 | 0.130 |
Why?
|
| Multivariate Analysis | 8 | 2016 | 1009 | 0.130 |
Why?
|
| Prednisone | 4 | 2025 | 251 | 0.130 |
Why?
|
| Calcaneus | 2 | 2007 | 40 | 0.130 |
Why?
|
| Logistic Models | 7 | 2016 | 1275 | 0.130 |
Why?
|
| Nuclear Proteins | 2 | 2016 | 750 | 0.120 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 2 | 2008 | 177 | 0.120 |
Why?
|
| Endoscopy | 1 | 2020 | 384 | 0.120 |
Why?
|
| Erythropoiesis | 2 | 2013 | 53 | 0.120 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2017 | 111 | 0.120 |
Why?
|
| Seasons | 1 | 1998 | 249 | 0.120 |
Why?
|
| Erlotinib Hydrochloride | 4 | 2011 | 86 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase 2 | 1 | 2016 | 25 | 0.120 |
Why?
|
| Hematologic Neoplasms | 2 | 2014 | 383 | 0.120 |
Why?
|
| Area Under Curve | 5 | 2019 | 340 | 0.120 |
Why?
|
| Mice, Inbred C57BL | 8 | 2020 | 3598 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2019 | 268 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2016 | 1394 | 0.120 |
Why?
|
| Hypersensitivity | 1 | 1998 | 166 | 0.120 |
Why?
|
| Peptide Termination Factors | 1 | 2016 | 6 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 2 | 2015 | 356 | 0.120 |
Why?
|
| Receptor, ErbB-3 | 1 | 2016 | 19 | 0.120 |
Why?
|
| Unrelated Donors | 1 | 2016 | 49 | 0.120 |
Why?
|
| Emergency Service, Hospital | 4 | 2003 | 634 | 0.120 |
Why?
|
| Guanine | 3 | 2014 | 194 | 0.120 |
Why?
|
| Forms and Records Control | 2 | 2009 | 15 | 0.120 |
Why?
|
| Risk Factors | 11 | 2014 | 6232 | 0.120 |
Why?
|
| Radiotherapy Dosage | 5 | 2023 | 479 | 0.120 |
Why?
|
| Dasatinib | 1 | 2015 | 38 | 0.120 |
Why?
|
| Gastrointestinal Transit | 4 | 2005 | 20 | 0.120 |
Why?
|
| Weight Loss | 1 | 1997 | 245 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 67 | 0.110 |
Why?
|
| Retroviridae | 1 | 2016 | 74 | 0.110 |
Why?
|
| Feasibility Studies | 4 | 2022 | 803 | 0.110 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 342 | 0.110 |
Why?
|
| Risk Assessment | 8 | 2019 | 2585 | 0.110 |
Why?
|
| Exanthema | 2 | 2014 | 43 | 0.110 |
Why?
|
| Mutagenesis, Insertional | 1 | 2016 | 103 | 0.110 |
Why?
|
| Gene Expression | 4 | 2014 | 1320 | 0.110 |
Why?
|
| Immunization | 4 | 2013 | 154 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 4 | 2025 | 323 | 0.110 |
Why?
|
| Fathers | 1 | 2015 | 46 | 0.110 |
Why?
|
| Critical Care | 1 | 2019 | 483 | 0.110 |
Why?
|
| Forced Expiratory Volume | 3 | 2008 | 138 | 0.110 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2015 | 46 | 0.110 |
Why?
|
| Amino Acid Substitution | 1 | 2016 | 334 | 0.110 |
Why?
|
| Cancer Vaccines | 2 | 2013 | 168 | 0.110 |
Why?
|
| Family Health | 1 | 2015 | 156 | 0.110 |
Why?
|
| Colon | 1 | 2019 | 562 | 0.110 |
Why?
|
| Wnt Signaling Pathway | 1 | 2016 | 105 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2015 | 75 | 0.110 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 171 | 0.110 |
Why?
|
| Urologic Neoplasms | 1 | 2016 | 82 | 0.110 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 104 | 0.110 |
Why?
|
| Toxoplasmosis | 1 | 2015 | 68 | 0.110 |
Why?
|
| Wood | 3 | 2021 | 23 | 0.110 |
Why?
|
| Rheumatic Heart Disease | 1 | 1995 | 31 | 0.110 |
Why?
|
| Hydrocephalus | 1 | 2015 | 80 | 0.110 |
Why?
|
| Child | 15 | 2016 | 7699 | 0.110 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2015 | 85 | 0.110 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 53 | 0.110 |
Why?
|
| Patient Education as Topic | 2 | 2000 | 417 | 0.110 |
Why?
|
| Spleen | 2 | 2013 | 375 | 0.110 |
Why?
|
| Organoplatinum Compounds | 1 | 2014 | 95 | 0.110 |
Why?
|
| Cluster Analysis | 1 | 2015 | 402 | 0.110 |
Why?
|
| Cell Line, Tumor | 7 | 2019 | 2888 | 0.100 |
Why?
|
| Immunologic Memory | 2 | 2013 | 188 | 0.100 |
Why?
|
| Myocarditis | 1 | 1995 | 60 | 0.100 |
Why?
|
| Urinary Catheters | 1 | 2014 | 7 | 0.100 |
Why?
|
| Testosterone | 3 | 2018 | 265 | 0.100 |
Why?
|
| Lymph Node Excision | 1 | 2015 | 238 | 0.100 |
Why?
|
| Gene Amplification | 1 | 2014 | 142 | 0.100 |
Why?
|
| Angiopoietin-2 | 1 | 2014 | 23 | 0.100 |
Why?
|
| Indazoles | 4 | 2016 | 63 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 109 | 0.100 |
Why?
|
| Genes, APC | 1 | 2013 | 25 | 0.100 |
Why?
|
| Urinary Catheterization | 1 | 2014 | 40 | 0.100 |
Why?
|
| Antigens, CD34 | 2 | 2008 | 162 | 0.100 |
Why?
|
| Signal Transduction | 6 | 2015 | 3621 | 0.100 |
Why?
|
| Mass Spectrometry | 1 | 2014 | 191 | 0.100 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2008 | 158 | 0.100 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2013 | 42 | 0.100 |
Why?
|
| Stroke | 1 | 2023 | 1154 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2013 | 108 | 0.100 |
Why?
|
| Receptors, Growth Factor | 2 | 2011 | 52 | 0.100 |
Why?
|
| Immunohistochemistry | 6 | 2024 | 1815 | 0.100 |
Why?
|
| Oxidative Stress | 1 | 2016 | 489 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 502 | 0.100 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 44 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2013 | 113 | 0.100 |
Why?
|
| Blood Proteins | 1 | 2014 | 147 | 0.100 |
Why?
|
| Receptor, EphB4 | 1 | 2013 | 23 | 0.100 |
Why?
|
| Vincristine | 3 | 2025 | 102 | 0.100 |
Why?
|
| Transcription Factors | 4 | 2016 | 1717 | 0.100 |
Why?
|
| Infant | 6 | 2023 | 3332 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2013 | 121 | 0.100 |
Why?
|
| Food-Drug Interactions | 1 | 2013 | 19 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2668 | 0.100 |
Why?
|
| Age Factors | 7 | 2019 | 1967 | 0.090 |
Why?
|
| Drainage | 1 | 2014 | 176 | 0.090 |
Why?
|
| Histones | 3 | 2016 | 370 | 0.090 |
Why?
|
| Peritoneal Neoplasms | 2 | 2012 | 195 | 0.090 |
Why?
|
| Melanoma, Experimental | 1 | 2013 | 114 | 0.090 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2011 | 79 | 0.090 |
Why?
|
| Random Allocation | 4 | 2003 | 312 | 0.090 |
Why?
|
| Coombs Test | 2 | 2002 | 9 | 0.090 |
Why?
|
| src-Family Kinases | 1 | 2012 | 70 | 0.090 |
Why?
|
| Resource Allocation | 1 | 1993 | 65 | 0.090 |
Why?
|
| Public Opinion | 1 | 1993 | 55 | 0.090 |
Why?
|
| Erythroblastosis, Fetal | 2 | 2002 | 14 | 0.090 |
Why?
|
| Device Removal | 1 | 2014 | 170 | 0.090 |
Why?
|
| T-Lymphocytes | 5 | 2012 | 1327 | 0.090 |
Why?
|
| Doxorubicin | 3 | 2025 | 285 | 0.090 |
Why?
|
| Health Care Rationing | 1 | 1993 | 85 | 0.090 |
Why?
|
| Bevacizumab | 5 | 2012 | 255 | 0.090 |
Why?
|
| Pain | 3 | 2022 | 416 | 0.090 |
Why?
|
| Obesity | 2 | 1997 | 1061 | 0.090 |
Why?
|
| Proteins | 2 | 2016 | 804 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2024 | 200 | 0.090 |
Why?
|
| Albumins | 2 | 2025 | 127 | 0.090 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 245 | 0.090 |
Why?
|
| Cyclophosphamide | 2 | 2025 | 284 | 0.090 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2011 | 18 | 0.090 |
Why?
|
| Mice, Knockout | 4 | 2020 | 2207 | 0.090 |
Why?
|
| Peptides | 1 | 2015 | 669 | 0.090 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2013 | 291 | 0.090 |
Why?
|
| Carbon Monoxide | 3 | 2017 | 98 | 0.090 |
Why?
|
| Crohn Disease | 1 | 2019 | 844 | 0.090 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2002 | 61 | 0.090 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2013 | 199 | 0.090 |
Why?
|
| Carcinoma, Large Cell | 1 | 2011 | 37 | 0.090 |
Why?
|
| Food Contamination | 1 | 2011 | 37 | 0.090 |
Why?
|
| Ear, External | 1 | 1991 | 24 | 0.090 |
Why?
|
| Proteomics | 1 | 2014 | 279 | 0.090 |
Why?
|
| Attitude to Health | 1 | 1993 | 217 | 0.090 |
Why?
|
| Maintenance Chemotherapy | 2 | 2024 | 96 | 0.090 |
Why?
|
| Immunotherapy | 3 | 2024 | 819 | 0.090 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2002 | 156 | 0.080 |
Why?
|
| Thalidomide | 1 | 2011 | 57 | 0.080 |
Why?
|
| Cesarean Section | 4 | 2001 | 162 | 0.080 |
Why?
|
| Hydrazines | 2 | 2023 | 36 | 0.080 |
Why?
|
| Delivery, Obstetric | 3 | 1998 | 120 | 0.080 |
Why?
|
| Tissue Banks | 1 | 2011 | 16 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 3618 | 0.080 |
Why?
|
| Insulin | 7 | 1995 | 1227 | 0.080 |
Why?
|
| Gene Expression Profiling | 4 | 2020 | 1566 | 0.080 |
Why?
|
| Eating | 1 | 2011 | 164 | 0.080 |
Why?
|
| Diagnostic Tests, Routine | 1 | 1991 | 63 | 0.080 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2012 | 321 | 0.080 |
Why?
|
| Lymph Nodes | 4 | 2022 | 560 | 0.080 |
Why?
|
| Thoracic Neoplasms | 1 | 2011 | 64 | 0.080 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 461 | 0.080 |
Why?
|
| DNA-Binding Proteins | 4 | 2016 | 1255 | 0.080 |
Why?
|
| Databases, Factual | 2 | 2016 | 1090 | 0.080 |
Why?
|
| Triazoles | 2 | 2023 | 118 | 0.080 |
Why?
|
| Mouth Neoplasms | 2 | 2007 | 222 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2011 | 159 | 0.080 |
Why?
|
| Drug Interactions | 4 | 2019 | 239 | 0.080 |
Why?
|
| Risk | 4 | 2007 | 660 | 0.080 |
Why?
|
| Coronary Disease | 1 | 1991 | 227 | 0.080 |
Why?
|
| Breath Tests | 4 | 2002 | 59 | 0.080 |
Why?
|
| Morphine | 2 | 2002 | 127 | 0.080 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2009 | 15 | 0.080 |
Why?
|
| Acid Anhydride Hydrolases | 1 | 2010 | 13 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2020 | 2013 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 1 | 2010 | 37 | 0.080 |
Why?
|
| Schwann Cells | 1 | 2009 | 36 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 643 | 0.080 |
Why?
|
| DNA Replication | 2 | 2010 | 169 | 0.080 |
Why?
|
| Everolimus | 2 | 2022 | 35 | 0.080 |
Why?
|
| Lymphatic Metastasis | 5 | 2015 | 520 | 0.080 |
Why?
|
| Mice, Transgenic | 5 | 2013 | 1604 | 0.080 |
Why?
|
| Leukemia, Myeloid | 3 | 2007 | 241 | 0.080 |
Why?
|
| Practice Management, Medical | 1 | 2009 | 20 | 0.070 |
Why?
|
| Odds Ratio | 3 | 2015 | 726 | 0.070 |
Why?
|
| Mastectomy, Extended Radical | 1 | 1989 | 1 | 0.070 |
Why?
|
| United States | 9 | 2018 | 8193 | 0.070 |
Why?
|
| Radiography, Thoracic | 1 | 1991 | 331 | 0.070 |
Why?
|
| Antibodies, Protozoan | 3 | 2015 | 47 | 0.070 |
Why?
|
| Risk Management | 1 | 2009 | 45 | 0.070 |
Why?
|
| Quality of Health Care | 3 | 2001 | 391 | 0.070 |
Why?
|
| Ultrasonography, Prenatal | 2 | 2021 | 152 | 0.070 |
Why?
|
| Withholding Treatment | 2 | 2024 | 131 | 0.070 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1850 | 0.070 |
Why?
|
| Patient Selection | 1 | 1993 | 725 | 0.070 |
Why?
|
| Neoplasms, Second Primary | 2 | 2003 | 244 | 0.070 |
Why?
|
| Glucocorticoids | 2 | 2018 | 370 | 0.070 |
Why?
|
| Outpatients | 1 | 2009 | 106 | 0.070 |
Why?
|
| Pulmonary Diffusing Capacity | 1 | 2008 | 24 | 0.070 |
Why?
|
| Medical Errors | 1 | 2009 | 93 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2024 | 2787 | 0.070 |
Why?
|
| Epidemiologic Methods | 1 | 2008 | 60 | 0.070 |
Why?
|
| Hypoglycemic Agents | 1 | 2012 | 412 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2021 | 159 | 0.070 |
Why?
|
| Drug Synergism | 3 | 2018 | 317 | 0.070 |
Why?
|
| Tumor Necrosis Factors | 1 | 2008 | 14 | 0.070 |
Why?
|
| Bystander Effect | 1 | 2008 | 14 | 0.070 |
Why?
|
| Quinoxalines | 1 | 2008 | 51 | 0.070 |
Why?
|
| Mutation, Missense | 1 | 2010 | 302 | 0.070 |
Why?
|
| Biopsy | 3 | 2023 | 1224 | 0.070 |
Why?
|
| Blood Component Removal | 1 | 2008 | 29 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2013 | 461 | 0.070 |
Why?
|
| Protein Kinases | 1 | 2009 | 212 | 0.070 |
Why?
|
| Cytogenetic Analysis | 3 | 2019 | 70 | 0.070 |
Why?
|
| Apoptosis | 4 | 2013 | 1752 | 0.070 |
Why?
|
| Neutropenia | 2 | 2008 | 211 | 0.070 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2008 | 111 | 0.070 |
Why?
|
| Insurance, Health | 1 | 2009 | 186 | 0.070 |
Why?
|
| Lymphocytes | 5 | 1990 | 461 | 0.070 |
Why?
|
| Blood Viscosity | 1 | 2007 | 14 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 1991 | 462 | 0.060 |
Why?
|
| Injections, Subcutaneous | 2 | 2024 | 141 | 0.060 |
Why?
|
| Absorptiometry, Photon | 1 | 2007 | 116 | 0.060 |
Why?
|
| Tubulin Modulators | 1 | 2007 | 23 | 0.060 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 5 | 2002 | 117 | 0.060 |
Why?
|
| DNA Repair | 4 | 2004 | 363 | 0.060 |
Why?
|
| Reishi | 1 | 2007 | 7 | 0.060 |
Why?
|
| Antigens | 1 | 2008 | 225 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2007 | 56 | 0.060 |
Why?
|
| Acute Disease | 4 | 2022 | 860 | 0.060 |
Why?
|
| C-Peptide | 5 | 1988 | 191 | 0.060 |
Why?
|
| Cell Survival | 4 | 2016 | 1014 | 0.060 |
Why?
|
| Bias | 2 | 1998 | 139 | 0.060 |
Why?
|
| Toxoplasmosis, Ocular | 1 | 2006 | 17 | 0.060 |
Why?
|
| Phosphorylcholine | 1 | 2006 | 22 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2018 | 1145 | 0.060 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2007 | 72 | 0.060 |
Why?
|
| Deoxyepinephrine | 1 | 1986 | 1 | 0.060 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2006 | 33 | 0.060 |
Why?
|
| Mexiletine | 1 | 1986 | 3 | 0.060 |
Why?
|
| Bryostatins | 1 | 2006 | 14 | 0.060 |
Why?
|
| Propylamines | 1 | 1986 | 7 | 0.060 |
Why?
|
| Antiprotozoal Agents | 1 | 2006 | 30 | 0.060 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2024 | 246 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2010 | 403 | 0.060 |
Why?
|
| Vision Disorders | 1 | 2006 | 74 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2008 | 479 | 0.060 |
Why?
|
| Muscles | 2 | 2023 | 179 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2007 | 218 | 0.060 |
Why?
|
| Bone Density | 3 | 2007 | 247 | 0.060 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2005 | 8 | 0.060 |
Why?
|
| Postoperative Care | 2 | 2014 | 236 | 0.060 |
Why?
|
| Birth Weight | 4 | 2017 | 150 | 0.060 |
Why?
|
| Bilirubin | 2 | 2004 | 135 | 0.060 |
Why?
|
| Analgesics, Opioid | 2 | 2002 | 539 | 0.060 |
Why?
|
| Jaundice, Neonatal | 2 | 2002 | 33 | 0.060 |
Why?
|
| Linear Models | 3 | 2015 | 424 | 0.060 |
Why?
|
| Norepinephrine | 1 | 1986 | 167 | 0.060 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2011 | 682 | 0.060 |
Why?
|
| Benzamides | 2 | 2022 | 260 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2006 | 700 | 0.060 |
Why?
|
| Hemolysis | 1 | 2005 | 66 | 0.060 |
Why?
|
| Myocardium | 6 | 1986 | 578 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 2 | 1998 | 244 | 0.060 |
Why?
|
| Epithelial Cells | 3 | 2022 | 709 | 0.060 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2015 | 373 | 0.060 |
Why?
|
| Blood Pressure Monitors | 1 | 2024 | 10 | 0.050 |
Why?
|
| Bone Marrow | 3 | 2013 | 418 | 0.050 |
Why?
|
| Carrier Proteins | 2 | 1985 | 667 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2007 | 462 | 0.050 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2007 | 244 | 0.050 |
Why?
|
| Placebos | 3 | 2012 | 209 | 0.050 |
Why?
|
| Thyrotoxicosis | 1 | 2004 | 18 | 0.050 |
Why?
|
| Breech Presentation | 2 | 1994 | 12 | 0.050 |
Why?
|
| Methyltransferases | 4 | 1990 | 218 | 0.050 |
Why?
|
| Cytarabine | 2 | 2020 | 218 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2006 | 240 | 0.050 |
Why?
|
| Barrett Esophagus | 1 | 2005 | 94 | 0.050 |
Why?
|
| Plant Preparations | 1 | 2004 | 20 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2008 | 52 | 0.050 |
Why?
|
| Dopamine | 1 | 1986 | 280 | 0.050 |
Why?
|
| Fractures, Bone | 1 | 2006 | 160 | 0.050 |
Why?
|
| Quinolones | 1 | 2004 | 57 | 0.050 |
Why?
|
| Glutathione | 1 | 2004 | 108 | 0.050 |
Why?
|
| Uterine Diseases | 2 | 2001 | 19 | 0.050 |
Why?
|
| Uterine Hemorrhage | 2 | 2001 | 22 | 0.050 |
Why?
|
| Genome, Human | 1 | 2009 | 832 | 0.050 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2025 | 105 | 0.050 |
Why?
|
| BCG Vaccine | 1 | 2024 | 43 | 0.050 |
Why?
|
| Models, Theoretical | 1 | 2007 | 508 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 1 | 2004 | 35 | 0.050 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2024 | 98 | 0.050 |
Why?
|
| Lymphoma, T-Cell | 1 | 2004 | 60 | 0.050 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2004 | 58 | 0.050 |
Why?
|
| Suramin | 1 | 2004 | 25 | 0.050 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 564 | 0.050 |
Why?
|
| Arrhythmias, Cardiac | 1 | 1986 | 237 | 0.050 |
Why?
|
| Nimodipine | 1 | 2003 | 12 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 1987 | 428 | 0.050 |
Why?
|
| Body Weights and Measures | 1 | 2003 | 25 | 0.050 |
Why?
|
| Abortion, Spontaneous | 1 | 2004 | 74 | 0.050 |
Why?
|
| Circadian Rhythm | 2 | 2009 | 295 | 0.050 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2004 | 117 | 0.050 |
Why?
|
| Warfarin | 1 | 2004 | 108 | 0.050 |
Why?
|
| Receptors, Cell Surface | 1 | 1985 | 291 | 0.050 |
Why?
|
| Equipment Design | 1 | 2024 | 427 | 0.050 |
Why?
|
| Urban Population | 3 | 2003 | 246 | 0.050 |
Why?
|
| Health Status | 2 | 1999 | 385 | 0.050 |
Why?
|
| Injections, Intravenous | 6 | 2005 | 212 | 0.050 |
Why?
|
| ras Proteins | 1 | 2004 | 137 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 135 | 0.050 |
Why?
|
| Phytotherapy | 1 | 2004 | 139 | 0.050 |
Why?
|
| Patient Participation | 1 | 2025 | 246 | 0.050 |
Why?
|
| Angiography | 1 | 2003 | 194 | 0.050 |
Why?
|
| Hydroxyurea | 2 | 2014 | 233 | 0.050 |
Why?
|
| Blood Transfusion | 2 | 2001 | 180 | 0.050 |
Why?
|
| Genomics | 2 | 2023 | 898 | 0.050 |
Why?
|
| Thyrotropin | 1 | 2004 | 328 | 0.050 |
Why?
|
| Panax | 1 | 2004 | 171 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2023 | 145 | 0.050 |
Why?
|
| Imides | 1 | 2022 | 27 | 0.050 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 2022 | 31 | 0.050 |
Why?
|
| Rh Isoimmunization | 1 | 2002 | 5 | 0.050 |
Why?
|
| Asparaginase | 1 | 2022 | 38 | 0.050 |
Why?
|
| Proteasome Inhibitors | 1 | 2022 | 52 | 0.050 |
Why?
|
| Mice, Inbred C3H | 2 | 2013 | 370 | 0.050 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2018 | 213 | 0.050 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2022 | 20 | 0.050 |
Why?
|
| Colonic Pouches | 1 | 2003 | 99 | 0.050 |
Why?
|
| Omeprazole | 1 | 2022 | 11 | 0.050 |
Why?
|
| Succinylcholine | 1 | 2022 | 14 | 0.050 |
Why?
|
| Proctocolectomy, Restorative | 1 | 2003 | 117 | 0.050 |
Why?
|
| Hydralazine | 1 | 2022 | 22 | 0.050 |
Why?
|
| Intracranial Hemorrhages | 1 | 2023 | 138 | 0.040 |
Why?
|
| Pelvis | 1 | 2022 | 106 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2024 | 720 | 0.040 |
Why?
|
| Peripheral Nervous System | 1 | 2002 | 21 | 0.040 |
Why?
|
| Flow Cytometry | 3 | 2012 | 720 | 0.040 |
Why?
|
| Quaternary Ammonium Compounds | 4 | 2005 | 82 | 0.040 |
Why?
|
| Mass Screening | 1 | 2007 | 745 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2022 | 57 | 0.040 |
Why?
|
| Radiotherapy, High-Energy | 2 | 2010 | 43 | 0.040 |
Why?
|
| Thyroid Hormones | 1 | 2004 | 358 | 0.040 |
Why?
|
| Oxycodone | 1 | 2022 | 35 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 2 | 1995 | 303 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2022 | 53 | 0.040 |
Why?
|
| Activities of Daily Living | 2 | 1999 | 214 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2013 | 216 | 0.040 |
Why?
|
| Uterine Rupture | 1 | 2001 | 7 | 0.040 |
Why?
|
| Trial of Labor | 1 | 2001 | 6 | 0.040 |
Why?
|
| Nitriles | 1 | 2022 | 171 | 0.040 |
Why?
|
| Office Management | 1 | 1981 | 1 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2003 | 764 | 0.040 |
Why?
|
| Filing | 1 | 1981 | 3 | 0.040 |
Why?
|
| Patient Satisfaction | 2 | 2003 | 511 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2021 | 77 | 0.040 |
Why?
|
| Geriatric Assessment | 1 | 2003 | 193 | 0.040 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2022 | 285 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2004 | 365 | 0.040 |
Why?
|
| Smoking | 2 | 2016 | 674 | 0.040 |
Why?
|
| Desipramine | 1 | 2001 | 9 | 0.040 |
Why?
|
| Computers | 1 | 1981 | 102 | 0.040 |
Why?
|
| Obstetric Labor Complications | 1 | 2001 | 33 | 0.040 |
Why?
|
| Housing | 1 | 2021 | 51 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2019 | 2572 | 0.040 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2020 | 19 | 0.040 |
Why?
|
| Health Services for the Aged | 1 | 2001 | 32 | 0.040 |
Why?
|
| Triazolam | 1 | 2000 | 5 | 0.040 |
Why?
|
| Paroxetine | 1 | 2001 | 26 | 0.040 |
Why?
|
| Fetal Growth Retardation | 1 | 2021 | 73 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 98 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2021 | 68 | 0.040 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2000 | 12 | 0.040 |
Why?
|
| Thrombectomy | 1 | 2023 | 260 | 0.040 |
Why?
|
| Hepatocyte Growth Factor | 2 | 2011 | 86 | 0.040 |
Why?
|
| Anti-Anxiety Agents | 1 | 2000 | 23 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2010 | 889 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2004 | 486 | 0.040 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2001 | 212 | 0.040 |
Why?
|
| Human papillomavirus 16 | 1 | 2020 | 45 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2022 | 299 | 0.040 |
Why?
|
| Precision Medicine | 1 | 2025 | 503 | 0.040 |
Why?
|
| HLA Antigens | 1 | 2001 | 238 | 0.040 |
Why?
|
| Fetus | 1 | 2021 | 237 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2024 | 617 | 0.040 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2023 | 336 | 0.040 |
Why?
|
| Ethylnitrosourea | 2 | 2013 | 30 | 0.040 |
Why?
|
| Administration, Intravenous | 1 | 2020 | 64 | 0.040 |
Why?
|
| Drug Utilization Review | 1 | 1999 | 14 | 0.040 |
Why?
|
| Mucositis | 2 | 2010 | 18 | 0.040 |
Why?
|
| Sickness Impact Profile | 1 | 1999 | 29 | 0.040 |
Why?
|
| Mortality | 1 | 2001 | 159 | 0.040 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2020 | 151 | 0.040 |
Why?
|
| Dogs | 3 | 1998 | 639 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 1999 | 22 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2001 | 174 | 0.040 |
Why?
|
| Medication Errors | 1 | 1999 | 36 | 0.040 |
Why?
|
| Methadone | 1 | 2000 | 54 | 0.040 |
Why?
|
| Prevalence | 2 | 2015 | 1383 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 4 | 2004 | 1028 | 0.040 |
Why?
|
| Dose-Response Relationship, Radiation | 2 | 2018 | 193 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 184 | 0.040 |
Why?
|
| Carcinoma in Situ | 1 | 1999 | 54 | 0.040 |
Why?
|
| Gestational Age | 2 | 2017 | 341 | 0.040 |
Why?
|
| Catheterization, Peripheral | 1 | 1999 | 62 | 0.040 |
Why?
|
| Retreatment | 1 | 2019 | 107 | 0.040 |
Why?
|
| Constipation | 1 | 2000 | 68 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 763 | 0.040 |
Why?
|
| Leukapheresis | 1 | 1999 | 16 | 0.040 |
Why?
|
| Emergencies | 1 | 1999 | 122 | 0.040 |
Why?
|
| Intraoperative Period | 1 | 2019 | 93 | 0.040 |
Why?
|
| Community Health Services | 1 | 2000 | 81 | 0.040 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 288 | 0.040 |
Why?
|
| Diarrhea | 2 | 2011 | 180 | 0.040 |
Why?
|
| Birth Rate | 1 | 1998 | 12 | 0.040 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2023 | 568 | 0.040 |
Why?
|
| Abiraterone Acetate | 1 | 2018 | 14 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 977 | 0.040 |
Why?
|
| Biliary Tract Neoplasms | 1 | 2019 | 38 | 0.040 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1999 | 114 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2000 | 169 | 0.030 |
Why?
|
| Antigens, Differentiation | 1 | 1998 | 125 | 0.030 |
Why?
|
| Carcinogenesis | 1 | 2020 | 241 | 0.030 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 1998 | 677 | 0.030 |
Why?
|
| Fatigue | 2 | 2011 | 187 | 0.030 |
Why?
|
| Singapore | 1 | 2018 | 14 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2018 | 46 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 1998 | 150 | 0.030 |
Why?
|
| Point-of-Care Systems | 1 | 2019 | 155 | 0.030 |
Why?
|
| Skin Tests | 1 | 1998 | 53 | 0.030 |
Why?
|
| Hysterectomy | 1 | 2000 | 174 | 0.030 |
Why?
|
| Mites | 1 | 1998 | 17 | 0.030 |
Why?
|
| Cross Infection | 1 | 1999 | 155 | 0.030 |
Why?
|
| Dehydroepiandrosterone | 1 | 2018 | 47 | 0.030 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 1999 | 166 | 0.030 |
Why?
|
| Contrast Media | 2 | 2016 | 1011 | 0.030 |
Why?
|
| Affect | 1 | 2001 | 410 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2020 | 358 | 0.030 |
Why?
|
| Monocytes | 1 | 1999 | 219 | 0.030 |
Why?
|
| Reoperation | 1 | 2001 | 726 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2010 | 106 | 0.030 |
Why?
|
| Immunoglobulin M | 2 | 2015 | 153 | 0.030 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 1 | 2018 | 61 | 0.030 |
Why?
|
| Islets of Langerhans | 3 | 1994 | 568 | 0.030 |
Why?
|
| Cats | 1 | 1998 | 282 | 0.030 |
Why?
|
| Body Constitution | 1 | 1997 | 26 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2020 | 354 | 0.030 |
Why?
|
| Piperazines | 2 | 2011 | 306 | 0.030 |
Why?
|
| Incidence | 3 | 2015 | 1777 | 0.030 |
Why?
|
| Nephrotic Syndrome | 1 | 1997 | 34 | 0.030 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 1998 | 53 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 1784 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2000 | 349 | 0.030 |
Why?
|
| Psychomotor Performance | 1 | 2001 | 508 | 0.030 |
Why?
|
| Fasting | 1 | 2018 | 166 | 0.030 |
Why?
|
| Cell Line | 5 | 2009 | 2482 | 0.030 |
Why?
|
| Epigenesis, Genetic | 2 | 2014 | 588 | 0.030 |
Why?
|
| Acetaminophen | 1 | 1998 | 63 | 0.030 |
Why?
|
| Infant Mortality | 2 | 1994 | 68 | 0.030 |
Why?
|
| Leukocytes | 1 | 1998 | 212 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2019 | 289 | 0.030 |
Why?
|
| Alcoholism | 1 | 1999 | 197 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 1998 | 138 | 0.030 |
Why?
|
| Penicillamine | 1 | 1997 | 12 | 0.030 |
Why?
|
| Environmental Monitoring | 1 | 2017 | 93 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1031 | 0.030 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 146 | 0.030 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 2023 | 0.030 |
Why?
|
| Urinary Bladder Neck Obstruction | 1 | 1997 | 26 | 0.030 |
Why?
|
| Liver Cirrhosis, Biliary | 1 | 1997 | 28 | 0.030 |
Why?
|
| Religion | 1 | 1997 | 101 | 0.030 |
Why?
|
| Dust | 1 | 1997 | 26 | 0.030 |
Why?
|
| Household Products | 1 | 2016 | 9 | 0.030 |
Why?
|
| Biofuels | 1 | 2016 | 11 | 0.030 |
Why?
|
| Patient Safety | 1 | 2019 | 235 | 0.030 |
Why?
|
| Cystoscopy | 1 | 1997 | 37 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2017 | 99 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2001 | 424 | 0.030 |
Why?
|
| Lidocaine | 1 | 1997 | 62 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2019 | 306 | 0.030 |
Why?
|
| Antirheumatic Agents | 1 | 1997 | 65 | 0.030 |
Why?
|
| Schools | 1 | 1997 | 93 | 0.030 |
Why?
|
| Body Mass Index | 2 | 1997 | 850 | 0.030 |
Why?
|
| Unsupervised Machine Learning | 1 | 2016 | 9 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 1999 | 330 | 0.030 |
Why?
|
| Social Support | 1 | 1998 | 246 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2016 | 518 | 0.030 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 480 | 0.030 |
Why?
|
| Creatinine | 1 | 1997 | 313 | 0.030 |
Why?
|
| Body Weight | 1 | 1997 | 455 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 71 | 0.030 |
Why?
|
| Colitis, Ulcerative | 1 | 2003 | 824 | 0.030 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2017 | 174 | 0.030 |
Why?
|
| Loss of Heterozygosity | 2 | 2010 | 84 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 1997 | 85 | 0.030 |
Why?
|
| Cell Differentiation | 3 | 2009 | 1646 | 0.030 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2016 | 139 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2010 | 780 | 0.030 |
Why?
|
| Premature Birth | 1 | 2017 | 131 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1997 | 117 | 0.030 |
Why?
|
| DNA Methylation | 2 | 2016 | 730 | 0.030 |
Why?
|
| Diabetes Mellitus | 2 | 2000 | 811 | 0.030 |
Why?
|
| Agglutination Tests | 1 | 2015 | 11 | 0.030 |
Why?
|
| Serogroup | 1 | 2015 | 10 | 0.030 |
Why?
|
| Karnofsky Performance Status | 1 | 2015 | 43 | 0.030 |
Why?
|
| Heart | 4 | 1986 | 527 | 0.030 |
Why?
|
| Margins of Excision | 1 | 2016 | 49 | 0.030 |
Why?
|
| Infusions, Intravenous | 2 | 2008 | 412 | 0.030 |
Why?
|
| Waiting Lists | 1 | 1997 | 237 | 0.030 |
Why?
|
| Mice, Mutant Strains | 1 | 2016 | 217 | 0.030 |
Why?
|
| Prostatic Hyperplasia | 1 | 1997 | 104 | 0.030 |
Why?
|
| Snake Venoms | 1 | 2015 | 10 | 0.030 |
Why?
|
| Reference Values | 5 | 1998 | 612 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2018 | 615 | 0.030 |
Why?
|
| Sex Factors | 1 | 2019 | 1138 | 0.030 |
Why?
|
| Visual Acuity | 2 | 2006 | 198 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2016 | 282 | 0.030 |
Why?
|
| Heart Failure | 1 | 1986 | 1491 | 0.030 |
Why?
|
| Pain Measurement | 1 | 1997 | 401 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2014 | 22 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2016 | 426 | 0.030 |
Why?
|
| Recombinant Proteins | 2 | 2008 | 993 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 821 | 0.030 |
Why?
|
| Air Pollution | 1 | 2016 | 119 | 0.030 |
Why?
|
| Exercise | 2 | 2014 | 380 | 0.030 |
Why?
|
| Mastectomy, Segmental | 2 | 2010 | 115 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 76 | 0.030 |
Why?
|
| Cells, Cultured | 2 | 2013 | 2855 | 0.030 |
Why?
|
| Anemia, Sickle Cell | 1 | 1997 | 158 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 1994 | 62 | 0.030 |
Why?
|
| Blood Glucose | 6 | 2000 | 913 | 0.030 |
Why?
|
| Skin Window Technique | 1 | 2013 | 3 | 0.030 |
Why?
|
| Attitude of Health Personnel | 1 | 2019 | 685 | 0.030 |
Why?
|
| Hospitals | 1 | 1997 | 336 | 0.030 |
Why?
|
| Anemia, Macrocytic | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, Chemokine | 1 | 2013 | 30 | 0.030 |
Why?
|
| Taxoids | 1 | 2014 | 127 | 0.030 |
Why?
|
| CD11b Antigen | 1 | 2013 | 35 | 0.030 |
Why?
|
| Genes, Lethal | 1 | 2013 | 49 | 0.030 |
Why?
|
| Pemetrexed | 1 | 2014 | 76 | 0.030 |
Why?
|
| Erythroblasts | 1 | 2013 | 27 | 0.030 |
Why?
|
| Glutamates | 1 | 2014 | 84 | 0.030 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 658 | 0.030 |
Why?
|
| Erythrocyte Count | 1 | 2013 | 21 | 0.020 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 1986 | 133 | 0.020 |
Why?
|
| Cellular Microenvironment | 1 | 2013 | 33 | 0.020 |
Why?
|
| Pyrimethamine | 2 | 2006 | 19 | 0.020 |
Why?
|
| Aspirin | 1 | 1995 | 169 | 0.020 |
Why?
|
| Sulfadiazine | 2 | 2006 | 23 | 0.020 |
Why?
|
| S Phase | 2 | 2010 | 64 | 0.020 |
Why?
|
| Genes, ras | 1 | 2013 | 97 | 0.020 |
Why?
|
| Quality Control | 2 | 1986 | 130 | 0.020 |
Why?
|
| Muscular Dystrophies | 2 | 1984 | 54 | 0.020 |
Why?
|
| Ovalbumin | 1 | 2013 | 105 | 0.020 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 1995 | 196 | 0.020 |
Why?
|
| Erythropoietin | 1 | 2013 | 90 | 0.020 |
Why?
|
| Autopsy | 1 | 2013 | 131 | 0.020 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2013 | 136 | 0.020 |
Why?
|
| Imidazoles | 1 | 2013 | 142 | 0.020 |
Why?
|
| Cystic Fibrosis | 1 | 1994 | 123 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 1995 | 391 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2013 | 353 | 0.020 |
Why?
|
| Moral Obligations | 1 | 1993 | 54 | 0.020 |
Why?
|
| Epitopes | 1 | 2013 | 258 | 0.020 |
Why?
|
| Kidney | 1 | 1997 | 1123 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 1993 | 69 | 0.020 |
Why?
|
| Heterozygote | 1 | 2013 | 390 | 0.020 |
Why?
|
| Serotyping | 1 | 2012 | 28 | 0.020 |
Why?
|
| Life Support Care | 1 | 1993 | 58 | 0.020 |
Why?
|
| Cell Membrane | 5 | 1986 | 673 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2014 | 743 | 0.020 |
Why?
|
| Infant, Premature | 1 | 1994 | 306 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 1992 | 62 | 0.020 |
Why?
|
| Antigen Presentation | 1 | 2013 | 234 | 0.020 |
Why?
|
| United States Department of Defense | 1 | 2011 | 4 | 0.020 |
Why?
|
| Autoantibodies | 1 | 1993 | 287 | 0.020 |
Why?
|
| Oocysts | 1 | 2011 | 8 | 0.020 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2011 | 16 | 0.020 |
Why?
|
| Glucose | 3 | 1995 | 704 | 0.020 |
Why?
|
| Orchiectomy | 1 | 2011 | 64 | 0.020 |
Why?
|
| Hospitalization | 1 | 1997 | 991 | 0.020 |
Why?
|
| Death, Sudden | 1 | 1991 | 44 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 556 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2013 | 480 | 0.020 |
Why?
|
| Virulence | 1 | 2012 | 280 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2012 | 267 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2009 | 580 | 0.020 |
Why?
|
| North America | 1 | 2011 | 210 | 0.020 |
Why?
|
| Pleural Effusion | 1 | 1991 | 42 | 0.020 |
Why?
|
| Kidney Diseases | 1 | 2013 | 314 | 0.020 |
Why?
|
| STAT3 Transcription Factor | 1 | 2011 | 91 | 0.020 |
Why?
|
| Pneumothorax | 1 | 1991 | 51 | 0.020 |
Why?
|
| Phospholipids | 2 | 2006 | 109 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 2 | 2002 | 212 | 0.020 |
Why?
|
| Herbicides | 1 | 1990 | 25 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 166 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2002 | 679 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2011 | 410 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2011 | 370 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2013 | 822 | 0.020 |
Why?
|
| Models, Biological | 3 | 2013 | 1809 | 0.020 |
Why?
|
| Aphidicolin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Replication Origin | 1 | 2010 | 4 | 0.020 |
Why?
|
| Hospitals, University | 2 | 2001 | 192 | 0.020 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2010 | 45 | 0.020 |
Why?
|
| Tissue Donors | 1 | 1994 | 581 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2010 | 73 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 245 | 0.020 |
Why?
|
| Paraffin Embedding | 1 | 2010 | 77 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2013 | 566 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2012 | 895 | 0.020 |
Why?
|
| Cell Movement | 1 | 2013 | 814 | 0.020 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2010 | 150 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2010 | 273 | 0.020 |
Why?
|
| Sister Chromatid Exchange | 1 | 1989 | 12 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2013 | 663 | 0.020 |
Why?
|
| Veterans | 1 | 1990 | 119 | 0.020 |
Why?
|
| Acetylation | 1 | 2009 | 151 | 0.020 |
Why?
|
| Castration | 1 | 2009 | 32 | 0.020 |
Why?
|
| Tamoxifen | 1 | 2010 | 176 | 0.020 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 66 | 0.020 |
Why?
|
| DNA Primers | 1 | 2010 | 530 | 0.020 |
Why?
|
| Genomic Instability | 1 | 2009 | 90 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 1991 | 216 | 0.020 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2009 | 49 | 0.020 |
Why?
|
| RNA, Messenger | 2 | 2006 | 2063 | 0.020 |
Why?
|
| Brachytherapy | 1 | 2010 | 139 | 0.020 |
Why?
|
| Demography | 1 | 2009 | 193 | 0.020 |
Why?
|
| Muscle Strength | 1 | 2009 | 51 | 0.020 |
Why?
|
| Pneumonia | 1 | 2010 | 195 | 0.020 |
Why?
|
| Morbidity | 2 | 1999 | 162 | 0.020 |
Why?
|
| Thiosemicarbazones | 1 | 2008 | 6 | 0.020 |
Why?
|
| Methemoglobinemia | 1 | 2008 | 10 | 0.020 |
Why?
|
| Filgrastim | 1 | 2008 | 56 | 0.020 |
Why?
|
| Neoplasms, Squamous Cell | 1 | 2008 | 19 | 0.020 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2008 | 41 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 2008 | 33 | 0.020 |
Why?
|
| Radiotherapy | 1 | 2010 | 325 | 0.020 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2008 | 85 | 0.020 |
Why?
|
| Imatinib Mesylate | 1 | 2008 | 128 | 0.020 |
Why?
|
| Mercaptoethylamines | 1 | 1988 | 52 | 0.020 |
Why?
|
| Tolonium Chloride | 1 | 2007 | 9 | 0.020 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2008 | 77 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2009 | 264 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 2007 | 102 | 0.020 |
Why?
|
| Cytological Techniques | 1 | 2007 | 30 | 0.020 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 239 | 0.020 |
Why?
|
| Coloring Agents | 1 | 2007 | 70 | 0.020 |
Why?
|
| Fluorescence | 1 | 2007 | 100 | 0.020 |
Why?
|
| Radiation-Protective Agents | 1 | 1988 | 98 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2008 | 144 | 0.020 |
Why?
|
| Rheology | 1 | 2007 | 38 | 0.020 |
Why?
|
| Microscopy, Electron | 5 | 1986 | 435 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2008 | 153 | 0.020 |
Why?
|
| Cell Proliferation | 1 | 2013 | 1790 | 0.020 |
Why?
|
| CD56 Antigen | 1 | 2007 | 18 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 312 | 0.020 |
Why?
|
| Thirst | 1 | 2007 | 19 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 1991 | 520 | 0.020 |
Why?
|
| Phenotype | 1 | 2013 | 2638 | 0.020 |
Why?
|
| Wechsler Scales | 1 | 2006 | 17 | 0.020 |
Why?
|
| Vision, Monocular | 1 | 2006 | 15 | 0.020 |
Why?
|
| Intelligence Tests | 1 | 2006 | 38 | 0.020 |
Why?
|
| Length of Stay | 2 | 2003 | 878 | 0.020 |
Why?
|
| Femur Neck | 1 | 2006 | 42 | 0.020 |
Why?
|
| Macula Lutea | 1 | 2006 | 17 | 0.020 |
Why?
|
| Language Tests | 1 | 2006 | 37 | 0.020 |
Why?
|
| Fractals | 1 | 2006 | 41 | 0.020 |
Why?
|
| Vision, Binocular | 1 | 2006 | 23 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 4 | 1988 | 118 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 2222 | 0.010 |
Why?
|
| Chemistry, Clinical | 1 | 1986 | 2 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2014 | 2558 | 0.010 |
Why?
|
| Mammography | 1 | 2010 | 504 | 0.010 |
Why?
|
| Physical Exertion | 1 | 1986 | 39 | 0.010 |
Why?
|
| Cricetinae | 2 | 2002 | 533 | 0.010 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.010 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 16 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 34 | 0.010 |
Why?
|
| Hip Joint | 1 | 2006 | 58 | 0.010 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2006 | 123 | 0.010 |
Why?
|
| Rest | 1 | 1986 | 52 | 0.010 |
Why?
|
| Chromatin | 1 | 2009 | 454 | 0.010 |
Why?
|
| Hyperbilirubinemia | 1 | 2005 | 20 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2006 | 80 | 0.010 |
Why?
|
| Cardiac Output | 1 | 1986 | 142 | 0.010 |
Why?
|
| Saxitoxin | 1 | 1985 | 8 | 0.010 |
Why?
|
| Gene Library | 1 | 2006 | 125 | 0.010 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 1986 | 123 | 0.010 |
Why?
|
| International Cooperation | 1 | 1986 | 132 | 0.010 |
Why?
|
| Cornified Envelope Proline-Rich Proteins | 1 | 2005 | 6 | 0.010 |
Why?
|
| GATA6 Transcription Factor | 1 | 2005 | 13 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2006 | 380 | 0.010 |
Why?
|
| Half-Life | 1 | 2005 | 89 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2006 | 300 | 0.010 |
Why?
|
| Folate Receptors, GPI-Anchored | 1 | 1985 | 2 | 0.010 |
Why?
|
| Pattern Recognition, Visual | 1 | 2006 | 163 | 0.010 |
Why?
|
| Azores | 1 | 2004 | 3 | 0.010 |
Why?
|
| Freeze Fracturing | 4 | 1985 | 11 | 0.010 |
Why?
|
| Zinc Fingers | 1 | 2004 | 59 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2004 | 43 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 370 | 0.010 |
Why?
|
| Genes, erbA | 1 | 2004 | 11 | 0.010 |
Why?
|
| Biological Availability | 1 | 2004 | 86 | 0.010 |
Why?
|
| Fetal Death | 2 | 1994 | 55 | 0.010 |
Why?
|
| Platinum | 1 | 2004 | 68 | 0.010 |
Why?
|
| Multigene Family | 1 | 2005 | 204 | 0.010 |
Why?
|
| International Normalized Ratio | 1 | 2004 | 38 | 0.010 |
Why?
|
| Oncogenes | 1 | 2004 | 102 | 0.010 |
Why?
|
| Dual Specificity Phosphatase 1 | 1 | 2004 | 17 | 0.010 |
Why?
|
| Sodium | 1 | 1985 | 330 | 0.010 |
Why?
|
| Protein Phosphatase 1 | 1 | 2004 | 31 | 0.010 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2004 | 47 | 0.010 |
Why?
|
| DNA | 1 | 2010 | 1274 | 0.010 |
Why?
|
| Surveys and Questionnaires | 2 | 2003 | 3022 | 0.010 |
Why?
|
| Fibroblast Growth Factors | 1 | 2004 | 89 | 0.010 |
Why?
|
| Ion Channels | 1 | 1985 | 259 | 0.010 |
Why?
|
| Socioeconomic Factors | 2 | 1999 | 663 | 0.010 |
Why?
|
| Defecation | 1 | 2003 | 26 | 0.010 |
Why?
|
| Surgical Stapling | 1 | 2003 | 18 | 0.010 |
Why?
|
| Stroke Volume | 1 | 1986 | 464 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2004 | 524 | 0.010 |
Why?
|
| Locomotion | 1 | 1984 | 150 | 0.010 |
Why?
|
| Intercellular Junctions | 1 | 1983 | 69 | 0.010 |
Why?
|
| Immediate-Early Proteins | 1 | 2004 | 161 | 0.010 |
Why?
|
| Lumbar Vertebrae | 1 | 2006 | 376 | 0.010 |
Why?
|
| DNA Damage | 1 | 2004 | 399 | 0.010 |
Why?
|
| Pedigree | 1 | 2004 | 980 | 0.010 |
Why?
|
| CHO Cells | 1 | 2002 | 188 | 0.010 |
Why?
|
| Leukocyte Count | 2 | 1999 | 215 | 0.010 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1982 | 100 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1986 | 747 | 0.010 |
Why?
|
| Glucuronides | 1 | 2002 | 34 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 613 | 0.010 |
Why?
|
| Physicians | 1 | 2009 | 685 | 0.010 |
Why?
|
| HLA-G Antigens | 1 | 2001 | 52 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 595 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 689 | 0.010 |
Why?
|
| Carcinoma, Bronchogenic | 1 | 1981 | 11 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 2001 | 66 | 0.010 |
Why?
|
| Immunologic Techniques | 1 | 1981 | 25 | 0.010 |
Why?
|
| Down-Regulation | 1 | 2002 | 529 | 0.010 |
Why?
|
| Cognition | 1 | 2006 | 673 | 0.010 |
Why?
|
| Poverty Areas | 1 | 2001 | 37 | 0.010 |
Why?
|
| Sleep, REM | 1 | 2000 | 49 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 1982 | 582 | 0.010 |
Why?
|
| Growth Hormone | 1 | 2000 | 97 | 0.010 |
Why?
|
| Medical Records | 1 | 1981 | 123 | 0.010 |
Why?
|
| Chickens | 3 | 1985 | 195 | 0.010 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2000 | 5 | 0.010 |
Why?
|
| Diabetic Foot | 1 | 2000 | 16 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2006 | 2037 | 0.010 |
Why?
|
| Polysomnography | 1 | 2000 | 154 | 0.010 |
Why?
|
| Lactulose | 1 | 2000 | 22 | 0.010 |
Why?
|
| Hyperglycemia | 2 | 1994 | 186 | 0.010 |
Why?
|
| Pregnancy Complications, Parasitic | 1 | 2000 | 17 | 0.010 |
Why?
|
| Sterilization, Reproductive | 1 | 2000 | 12 | 0.010 |
Why?
|
| Phlebitis | 1 | 1999 | 1 | 0.010 |
Why?
|
| Placenta Accreta | 1 | 2000 | 10 | 0.010 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2000 | 34 | 0.010 |
Why?
|
| Cell Transformation, Viral | 2 | 1990 | 38 | 0.010 |
Why?
|
| Midwestern United States | 1 | 2000 | 92 | 0.010 |
Why?
|
| Colony Count, Microbial | 1 | 1999 | 39 | 0.010 |
Why?
|
| Peptic Ulcer | 1 | 1999 | 18 | 0.010 |
Why?
|
| Rats, Inbred Strains | 3 | 1985 | 300 | 0.010 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2000 | 55 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 1999 | 45 | 0.010 |
Why?
|
| Lymphocyte Transfusion | 1 | 1999 | 39 | 0.010 |
Why?
|
| Emergency Treatment | 1 | 2000 | 47 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1986 | 687 | 0.010 |
Why?
|
| Accidental Falls | 1 | 1999 | 48 | 0.010 |
Why?
|
| Eye Diseases | 1 | 2000 | 59 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 1307 | 0.010 |
Why?
|
| Procarbazine | 2 | 1990 | 27 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2000 | 81 | 0.010 |
Why?
|
| Prenatal Diagnosis | 1 | 2000 | 107 | 0.010 |
Why?
|
| Cicatrix | 1 | 2000 | 79 | 0.010 |
Why?
|
| Herpesvirus 4, Human | 2 | 1990 | 124 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 1999 | 68 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 2000 | 306 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 2005 | 831 | 0.010 |
Why?
|
| Aging | 3 | 1993 | 771 | 0.010 |
Why?
|
| Cardiovascular Diseases | 2 | 1999 | 802 | 0.010 |
Why?
|
| Abatacept | 1 | 1998 | 89 | 0.010 |
Why?
|
| Diabetes Complications | 1 | 1999 | 176 | 0.010 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 1998 | 12 | 0.010 |
Why?
|
| Intraoperative Complications | 1 | 2000 | 194 | 0.010 |
Why?
|
| Radius | 1 | 1998 | 30 | 0.010 |
Why?
|
| CTLA-4 Antigen | 1 | 1998 | 146 | 0.010 |
Why?
|
| Guideline Adherence | 1 | 2000 | 250 | 0.010 |
Why?
|
| Homeostasis | 1 | 2000 | 474 | 0.010 |
Why?
|
| Puberty | 1 | 1998 | 59 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 1948 | 0.010 |
Why?
|
| Nephrosis, Lipoid | 1 | 1997 | 6 | 0.010 |
Why?
|
| Nutritional Status | 1 | 1998 | 83 | 0.010 |
Why?
|
| Gastrointestinal Agents | 1 | 2000 | 197 | 0.010 |
Why?
|
| Cold Temperature | 1 | 1998 | 163 | 0.010 |
Why?
|
| Hormones | 1 | 1998 | 138 | 0.010 |
Why?
|
| Calcium | 2 | 1998 | 1196 | 0.010 |
Why?
|
| Glomerulosclerosis, Focal Segmental | 1 | 1997 | 38 | 0.010 |
Why?
|
| Mental Health | 1 | 1999 | 219 | 0.010 |
Why?
|
| Antigens, Plant | 1 | 1997 | 14 | 0.010 |
Why?
|
| Floors and Floorcoverings | 1 | 1997 | 7 | 0.010 |
Why?
|
| Age Distribution | 1 | 1997 | 208 | 0.010 |
Why?
|
| Lubrication | 1 | 1997 | 2 | 0.010 |
Why?
|
| Cystoscopes | 1 | 1997 | 2 | 0.010 |
Why?
|
| Dosage Forms | 1 | 1997 | 8 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2004 | 1445 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 1997 | 360 | 0.010 |
Why?
|
| Hospital Charges | 1 | 1997 | 31 | 0.010 |
Why?
|
| Antigens, CD | 1 | 1998 | 484 | 0.010 |
Why?
|
| Diet | 1 | 2000 | 469 | 0.010 |
Why?
|
| Physicians, Family | 1 | 1997 | 36 | 0.010 |
Why?
|
| Infusions, Parenteral | 2 | 1986 | 47 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 1997 | 102 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 1997 | 282 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2000 | 1568 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 1284 | 0.010 |
Why?
|
| Ambulatory Care | 1 | 1997 | 201 | 0.010 |
Why?
|
| Sheep | 2 | 1985 | 204 | 0.010 |
Why?
|
| Illinois | 1 | 1997 | 522 | 0.010 |
Why?
|
| Glucose Tolerance Test | 1 | 1995 | 239 | 0.010 |
Why?
|
| Residence Characteristics | 1 | 1997 | 224 | 0.010 |
Why?
|
| Rana pipiens | 2 | 1985 | 11 | 0.010 |
Why?
|
| Amylases | 1 | 1994 | 14 | 0.010 |
Why?
|
| Kinetics | 2 | 1988 | 1476 | 0.010 |
Why?
|
| Cell Separation | 1 | 1994 | 200 | 0.010 |
Why?
|
| Cadaver | 1 | 1994 | 200 | 0.010 |
Why?
|
| Rats | 3 | 1985 | 4072 | 0.010 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 1994 | 68 | 0.010 |
Why?
|
| Homozygote | 1 | 1994 | 212 | 0.010 |
Why?
|
| Mice, SCID | 1 | 1994 | 278 | 0.010 |
Why?
|
| Rabbits | 2 | 1985 | 581 | 0.010 |
Why?
|
| Marriage | 1 | 1993 | 23 | 0.010 |
Why?
|
| Nucleotides | 1 | 1993 | 93 | 0.010 |
Why?
|
| Fertility | 1 | 1993 | 120 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1992 | 139 | 0.010 |
Why?
|
| Autoantigens | 1 | 1993 | 145 | 0.010 |
Why?
|
| Glaucoma | 1 | 1992 | 36 | 0.010 |
Why?
|
| Islets of Langerhans Transplantation | 1 | 1994 | 286 | 0.010 |
Why?
|
| Liver | 2 | 1988 | 1231 | 0.010 |
Why?
|
| 2,4,5-Trichlorophenoxyacetic Acid | 1 | 1990 | 1 | 0.010 |
Why?
|
| 2,4-Dichlorophenoxyacetic Acid | 1 | 1990 | 2 | 0.010 |
Why?
|
| Agent Orange | 1 | 1990 | 2 | 0.010 |
Why?
|
| Vietnam | 1 | 1990 | 16 | 0.010 |
Why?
|
| Polychlorinated Dibenzodioxins | 1 | 1990 | 4 | 0.010 |
Why?
|
| Aerospace Medicine | 1 | 1990 | 17 | 0.010 |
Why?
|
| Physical Examination | 1 | 1990 | 149 | 0.000 |
Why?
|
| Heart Ventricles | 2 | 1985 | 664 | 0.000 |
Why?
|
| Mitomycins | 1 | 1989 | 12 | 0.000 |
Why?
|
| Methylnitronitrosoguanidine | 1 | 1989 | 16 | 0.000 |
Why?
|
| Mitomycin | 1 | 1989 | 30 | 0.000 |
Why?
|
| Skin Diseases | 1 | 1990 | 176 | 0.000 |
Why?
|
| Mechlorethamine | 1 | 1988 | 10 | 0.000 |
Why?
|
| Liver Diseases | 1 | 1990 | 249 | 0.000 |
Why?
|
| Vinblastine | 1 | 1988 | 84 | 0.000 |
Why?
|
| Radiation Genetics | 1 | 1988 | 7 | 0.000 |
Why?
|
| Cobalt Radioisotopes | 1 | 1988 | 19 | 0.000 |
Why?
|
| Bleomycin | 1 | 1988 | 102 | 0.000 |
Why?
|
| Neutrons | 1 | 1988 | 57 | 0.000 |
Why?
|
| Gamma Rays | 1 | 1988 | 72 | 0.000 |
Why?
|
| Dacarbazine | 1 | 1988 | 104 | 0.000 |
Why?
|
| Histocytochemistry | 1 | 1987 | 122 | 0.000 |
Why?
|
| Membrane Proteins | 1 | 1994 | 1285 | 0.000 |
Why?
|
| Environmental Exposure | 1 | 1990 | 405 | 0.000 |
Why?
|
| Immunoenzyme Techniques | 1 | 1987 | 291 | 0.000 |
Why?
|
| X-Rays | 1 | 1986 | 139 | 0.000 |
Why?
|
| Mathematics | 1 | 1986 | 178 | 0.000 |
Why?
|
| Xenopus | 1 | 1986 | 120 | 0.000 |
Why?
|
| Amphibian Proteins | 1 | 1985 | 4 | 0.000 |
Why?
|
| Statistics as Topic | 1 | 1986 | 230 | 0.000 |
Why?
|
| Chick Embryo | 1 | 1985 | 176 | 0.000 |
Why?
|
| Sarcolemma | 1 | 1985 | 31 | 0.000 |
Why?
|
| Femoral Artery | 1 | 1986 | 96 | 0.000 |
Why?
|
| Tetrodotoxin | 1 | 1985 | 49 | 0.000 |
Why?
|
| Radiation Tolerance | 1 | 1986 | 179 | 0.000 |
Why?
|
| Purkinje Fibers | 1 | 1985 | 28 | 0.000 |
Why?
|
| B-Lymphocytes | 1 | 1990 | 727 | 0.000 |
Why?
|
| Prednisolone | 1 | 1984 | 37 | 0.000 |
Why?
|
| Embryo, Nonmammalian | 1 | 1986 | 204 | 0.000 |
Why?
|
| Braces | 1 | 1984 | 15 | 0.000 |
Why?
|
| Tendons | 1 | 1984 | 47 | 0.000 |
Why?
|
| Diethylstilbestrol | 1 | 1984 | 121 | 0.000 |
Why?
|
| In Vitro Techniques | 1 | 1985 | 945 | 0.000 |
Why?
|
| Heart Atria | 1 | 1985 | 255 | 0.000 |
Why?
|
| Ventricular Function | 1 | 1983 | 41 | 0.000 |
Why?
|
| Binding Sites | 1 | 1985 | 1159 | 0.000 |
Why?
|
| Axilla | 1 | 1982 | 109 | 0.000 |
Why?
|
| Myocardial Contraction | 1 | 1983 | 193 | 0.000 |
Why?
|
| Species Specificity | 1 | 1983 | 690 | 0.000 |
Why?
|
| Action Potentials | 1 | 1985 | 611 | 0.000 |
Why?
|
| Muscle Contraction | 1 | 1982 | 269 | 0.000 |
Why?
|